ArticleThe European journal of health economics : HEPAC : health economics in prevention and care2018
A comparison of the responsiveness of EQ-5D-5L and the QOLIE-31P and mapping of QOLIE-31P to EQ-5D-5L in epilepsy.
Article in The European journal of health economics : HEPAC : health economics in prevention and care, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 2 syntheses or guidelines pooled it, 39 citations in OpenAlex.
- Psychometric properties of the EQ-5D-5L: a systematic review of the literature.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2021Pooled it
- Assessment of components included in published societal perspective or QALY outcome economic analyses for antiepileptic drug treatment in chronic epilepsy.Expert review of pharmacoeconomics & outcomes research · 2018Pooled it
- Effectiveness of Seizure Dogs for People With Severe Refractory Epilepsy: Results From the EPISODE Study.Neurology · 2024Trial
- Trajectories of quality of life, anxiety and depressive symptomatology, and health-related work productivity after first seizure events.Epilepsia open · 2026Article
- Development, psychometric validation, and correlates of the 15-item quality of life in epilepsy scale (QOLIE-15).Scientific reports · 2026Article
- Self-completed patient-reported outcome measures in adults with epilepsy: A review.Epilepsia open · 2026Review
- Sleep quality and its correlates in people with epilepsy: A multicenter cross-sectional study in Germany.Epilepsia · 2025Article
- Article
- A Cost-Utility Analysis of Add-On Cannabidiol Versus Usual Care Alone for the Treatment of Seizures Associated with Tuberous Sclerosis Complex in England and Wales.PharmacoEconomics - open · 2024Article
- Work productivity, quality of life, and care needs: An unfolding epilepsy burden revealed in the Australian Epilepsy Project pilot study.Epilepsia open · 2024Article
- Cost-Utility Analysis of Add-on Cannabidiol vs Usual Care Alone for the Treatment of Seizures in Patients With Treatment-Resistant Lennox-Gastaut Syndrome or Dravet Syndrome in the Netherlands.Journal of health economics and outcomes research · 2024Article
- Mapping analysis to predict SF-6D utilities from health outcomes in people with focal epilepsy.The European journal of health economics : HEPAC : health economics in prevention and care · 2023Article
- Determinants of quality of life in adults with epilepsy: a multicenter, cross-sectional study from Germany.Neurological research and practice · 2023Article
- Burden of migraine in patients attending Belgian headache specialists: real-world evidence from the BECOME study.Acta neurologica Belgica · 2023Article
- Generating EQ-5D-5L health utility scores from BASDAI and BASFI: a mapping study in patients with axial spondyloarthritis using longitudinal UK registry data.The European journal of health economics : HEPAC : health economics in prevention and care · 2022Article
- Assessment of Quality of Life 8-Dimension (AQoL-8D): translation, validation, and application in two Dutch trials in patients with epilepsy and schizophrenia.Expert review of pharmacoeconomics & outcomes research · 2022Article
- Burden of illness in people with medically refractory epilepsy who suffer from daily to weekly seizures: 12-month follow-up of participants in the EPISODE study.Frontiers in neurology · 2022Article
- Patient and Caregiver Health State Utilities in Tuberous Sclerosis Complex.PharmacoEconomics - open · 2022Article
- The use of patient-reported measures in epilepsy care: the Calgary Comprehensive Epilepsy Program experience.Journal of patient-reported outcomes · 2021Article
- Mapping of the World Health Organization's Disability Assessment Schedule 2.0 to disability weights using the Multi-Country Survey Study on Health and Responsiveness.International journal of methods in psychiatric research · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 4 countries.
Funding
Abstract
objectiveTo investigate the responsiveness of and correlation between the EQ-5D-5L and the QOLIE-31P in patients with epilepsy, and develop a mapping function to predict EQ-5D-5L values based on the QOLIE-31P for use in economic evaluations.
methodsThe dataset was derived from two clinical trials, the ZMILE study in the Netherlands and the SMILE study in the UK. In both studies, patients' quality of life using the EQ-5D-5L and QOLIE-31P was measured at baseline and 12 months follow-up. Spearman's correlations, effect sizes (EF) and standardized response means (SRM) were calculated for both the EQ-5D-5L and QOLIE-31P domains and sub scores. Mapping functions were derived using ordinary least square (OLS) and censored least absolute deviations models.
resultsA total of 509 patients were included in this study. Low to moderately strong significant correlations were found between both instruments. The EQ-5D-5L showed high ceiling effects and small EFs and SRMs, whereas the QOLIE-31P did not show ceiling effects and also showed small to moderate EFs and SRMs. Results of the different mapping functions indicate that the highest adjusted R
conclusionsResults presented in this study emphasize the shortcomings of the EQ-5D-5L in epilepsy and the importance of the development of condition-specific preference-based instruments which can be used within the QALY framework. In addition, the usefulness of the constructed mapping function in economic evaluations is questionable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.